ArticlePPAR research2010
PPARs in the Renal Regulation of Systemic Blood Pressure.
Article in PPAR research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Pooled it
- Exposure to phthalates and replacements during pregnancy in association with gestational blood pressure and hypertensive disorders of pregnancy.Environmental research · 2025Article
- Endocrine Disruptors in Child Obesity and Related Disorders: Early Critical Windows of Exposure.Current nutrition reports · 2025Review
- IGF1 and PPARG polymorphisms are associated with reduced estimated glomerular filtration rate in a cohort of children and adolescents with type 1 diabetes.Acta diabetologica · 2023Article
- Eating Disorders During Gestation: Implications for Mother's Health, Fetal Outcomes, and Epigenetic Changes.Frontiers in pediatrics · 2020Review
- Early-Life Environmental Exposures and Blood Pressure in Children.Journal of the American College of Cardiology · 2019Article
- Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.Current hypertension reports · 2018Review
- New Insights Regarding Genetic Aspects of Childhood Obesity: A Minireview.Frontiers in pediatrics · 2018Review
- Impact of Maternal Diet on the Epigenome during In Utero Life and the Developmental Programming of Diseases in Childhood and Adulthood.Nutrients · 2015Review
- Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis.TheScientificWorldJournal · 2014Article
- Peroxisome proliferator-activated receptor-γ protects against vascular aging.American journal of physiology. Regulatory, integrative and comparative physiology · 2012Article
- The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.PPAR research · 2012Article
- PPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome.Cardiovascular diabetology · 2011Article
- Protecting against vascular disease in brain.American journal of physiology. Heart and circulatory physiology · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research has revealed roles for the peroxisome proliferator activated receptor (PPAR) family of transcription factors in blood pressure regulation, expanding the possible therapeutic use of PPAR ligands. PPARalpha and PPARgamma modulate the renin-angiotensin-aldosterone system (RAAS), a major regulator of systemic blood pressure and interstitial fluid volume by transcriptional control of renin, angiotensinogen, angiotensin converting enzyme (ACE) and angiotensin II receptor 1 (AT-R1). Blockade of RAAS is an important therapeutic target in hypertension management and attenuates microvascular damage, glomerular inflammation and left ventricular hypertrophy in hypertensive patients and also show antidiabetic effects. The mechanisms underlying the benefits of RAAS inhibition appear to involve PPARgamma-regulated pathways. This review summarizes current knowledge on the role of PPARs in the transcriptional control of the RAAS and the possible use of PPAR ligands in the treatment of RAAS dependent hypertension.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.